Stockscreener 앱 받기
15.84
3.93%
-0.6488
전일 마감가:
$16.49
열려 있는:
$16.47
하루 거래량:
288
Relative Volume:
0.08
시가총액:
$185.62M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+3.60%
1개월 성능:
+0.00%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$16.47
$16.47
1주일 범위
$15.03
$17.96
52주 변동 폭
$15.03
$17.96
Imagenebio Inc Stock (IMA) Company Profile
명칭
Imagenebio Inc
전화
857-343-8292
주소
50 NORTHERN AVE., BOSTON
IMA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMA
Imagenebio Inc
|
16.47 | 185.62M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
384.12 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.60 | 60.58B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
419.54 | 54.99B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
679.57 | 42.25B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
295.35 | 32.93B | 3.81B | -644.79M | -669.77M | -6.24 |
Imagenebio Inc 주식(IMA)의 최신 뉴스
Wall Street Analysts Believe IMAGENEBIO INC (IMA) Could Rally 695.48%: Here's is How to Trade - MSN
ImageneBio Approves 2025 Inducement Plan for Employees - The Globe and Mail
ImageneBio board approves 2025 inducement plan for new employee equity awards - Investing.com Australia
ImagenBio Adopts 2025 Equity Inducement Plan to Retain Top Talent - AInvest
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
ImageneBio Grants Massive $9.6M Equity Package: New CEO Gets 436K Stock Options, 153K RSUs - Stock Titan
Imagenebio shares rise 7.26% premarket after insider bought shares worth $7.999.924. - AInvest
Insider Transactions Reported | ImageneBio(IMA)saw insider trading activity on 7/30/2025 - AInvest
Ikena Oncology Completes Merger, Becomes ImageneBio, Inc. - The Globe and Mail
Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Ikena Oncology Inc. (NASDAQ: IKNA) - MarketScreener
ImageneBio Appoints Kristin Yarema as CEO, Merges with Ikena Oncology, Raises $75M - AInvest
ImageneBio Launches on Nasdaq Following Merger, Raises $75M for Skin Treatment Development - CTOL Digital Solutions
Ikena Oncology shares fall 2.03% after-hours following acquisition by Inmagene Biopharmaceuticals. - AInvest
Ikena Oncology shares climb as Kristin Yarema named CEO of soon-to-merge ImageneBio - MSN
Ikena Oncology Completes Merger with Inmagene Biopharmaceuticals - TipRanks
ImageneBio's Strategic Rebirth: A Catalyst for Long-Term Shareholder Value in the Atopic Dermatitis Market - AInvest
Inmagene Biopharmaceuticals Announces Completion of Merger - GlobeNewswire
Biotech Merger: Inmagene-Ikena Forms ImageneBio with $75M Backing from Elite Healthcare Investors - Stock Titan
Ikena Oncology to implement 1-for-12 reverse stock split and rebrand as ImageneBio - Investing.com
Ikena Oncology Announces Reverse Stock Split and Rebrand - TipRanks
Ikena to Rebrand as ImageneBio, Start 1-for-12 Reverse Split 28 Jul 2025 | IKNA SEC FilingForm 8-K - Stock Titan
Ikena Oncology stock rises after naming Kristin Yarema as CEO of combined company By Investing.com - Investing.com South Africa
iKena Oncology appoints Yarema as CEO of ImageneBio - TipRanks
Ikena Oncology and Inmagene name Kristin Yarema as CEO of combined firm - Investing.com
Ikena Oncology and Inmagene Biopharmaceuticals Announce - GlobeNewswire
Ikena Oncology Approves Merger and Reverse Stock Split - The Globe and Mail
Ikena Oncology Stockholders Approve Merger With Inmagene Biopharmaceuticals - citybiz
Ikena announces 1-for-12 reverse stock split, approval of Inmagene merger - TipRanks
Ikena shareholders approve merger with Inmagene, reverse stock split By Investing.com - Investing.com India
Ikena Oncology Announces 1-for-12 Reverse Stock Split and Merger with Inmagene Biopharmaceuticals, to Trade as ImageneBio, Inc. on Nasdaq Under Ticker "IMA" - Nasdaq
Ikena shareholders approve merger with Inmagene, reverse stock split - Investing.com
Inmagene Doses First Patient in the ADAPTIVE Phase 2b Trial of IMG-007, a Nondepleting Anti-OX40 mAb with an Extended Half-life, in Patients with Moderate-to-Severe Atopic Dermatitis - GlobeNewswire
Inmagene Bio charts backdoor to U.S. listing with offshore acquisition - thebambooworks.com
Ikena Oncology and Inmagene Announce Merger and Fundraising - Yahoo Finance
Immunology biotech Inmagene to join Nasdaq through reverse merger with what's left of Ikena - Endpoints News
Imagenebio Inc (IMA) 재무 분석
Imagenebio Inc (IMA)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.70%
0.06%
자본화:
|
볼륨(24시간):